Page last updated: 2024-10-28

ha14-1 and Lung Neoplasms

ha14-1 has been researched along with Lung Neoplasms in 2 studies

ethyl 2-amino-6-bromo-4-(1-cyano-2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate: a BH3 mimetic; synergistic induction of apoptosis by simultaneous disruption of the Bcl-2 and MEK/MAPK pathways in acute myelogenous leukemia

Lung Neoplasms: Tumors or cancer of the LUNG.

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (50.00)29.6817
2010's1 (50.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Baranski, Z1
de Jong, Y1
Ilkova, T1
Peterse, EF1
Cleton-Jansen, AM1
van de Water, B1
Hogendoorn, PC1
Bovée, JV1
Danen, EH1
Doshi, JM1
Tian, D1
Xing, C1

Other Studies

2 other studies available for ha14-1 and Lung Neoplasms

ArticleYear
Pharmacological inhibition of Bcl-xL sensitizes osteosarcoma to doxorubicin.
    Oncotarget, 2015, Nov-03, Volume: 6, Issue:34

    Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; bcl-X Protein; Benzopyrans; Biphenyl Comp

2015
Structure-activity relationship studies of ethyl 2-amino-6-bromo-4-(1-cyano-2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate (HA 14-1), an antagonist for antiapoptotic Bcl-2 proteins to overcome drug resistance in cancer.
    Journal of medicinal chemistry, 2006, Dec-28, Volume: 49, Issue:26

    Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; bcl-X Protein; Benzopyrans; Carcino

2006